Nimotuzumab given concurrently with chemoradiotherapy demonstrated efficacy and favorable tolerability in patients with locally advanced cervical squamous cell carcinoma, according to data from a randomized, controlled, open-label, multicenter study.
Related Keywords
China , Peking , Beijing , Ping Jiang , Guangxi , , University Third Hospital , Department Of Radiation Oncology , Radiation Oncology , Peking University Third Hospital , Nimotuzumab With Chemoradiotherapy , Patients With Locally Advanced Cervical Squamous Cell Carcinoma ,
comparemela.com © 2020. All Rights Reserved.